Genelux (GNLX)

• Market cap: $149M
• 1 day: 8.22%
• 5 days: 16.18%
• 1 month: 23.82%
• 3 months: 49.06%
• 6 months: 4.5%
• Year to date: 63.9%
• 1 year: 47.94%
• 5 years: -35.77%
• 10 years: -35.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Employees: 24

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

6% more capital invested

Capital invested by funds: $19.7M [Q1] → $20.8M (+$1.13M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.02% less ownership

Funds ownership: 19.34% [Q1] → 19.32% (-0.02%) [Q2]

19% less funds holding

Funds holding: 74 [Q1] → 60 (-14) [Q2]

67% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 21

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10
• Avg. target: $10
• High target: $10

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

LUCID CAPITAL MARKETS Christopher Liu

$10

Buy Initiated

21 Jul 2025